Listed right here are the 5 corporations, what they diagram, and when GV invested:
Spero Therapeutics, a biopharmaceutical firm creating treatments for bacterial infections, started trading on the Nasdaq final fall and has a most modern market cap of $204.eight million.
GV led its Assortment C in March 2017 and its stake is now worth $15.Seventy 9 million, in response to FactSet.
Arsanis, which is engaged on antibody immunotherapies for infectious diseases, went public in November of ultimate year and has a market cap of $327.2 million. GV invested in its Assortment D in April 2017 and its stake is worth $10.62 million, in response to FactSet.
Arcus Bioscience, which develops cancer immunotherapies, went public in March and has a market cap of $657 million.
GV first invested in Arcus’ Assortment B in 2016 and again in its Assortment C in 2017, and its stake is worth $eighty.9 million, in response to FactSet.
ARMO Biosciences fights cancer by diagram of immunotherapy. It went public in January 2018 has a market cap of $1.1 billion. GV invested in its Assortment C besides to its Assortment C-1 in 2016 and 2017 respectively, and its stake is currently worth $Forty five.14 million.
Denali Therapeutics creates therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s and went public in December 2017 and currently has a market cap of $1.86 billion.
There would possibly perhaps be a lawful likelihood 2018 will lift extra pleasure: Nasdaq’s head of healthcare listings currently predicted that biotech M&A would perhaps be hot this year and that we would possibly perhaps look 30+ entire biotech IPOs.
GV portfolio firm 23andMe is anticipated to file prior to the stop of the year.
Commentaires récents